We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 21

Universities abroad experiment with no-fee licensing to drive biotech partnerships
  • Shook Hardy & Bacon LLP
  • Australia, Canada, European Union, United Kingdom, USA
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies


EU Medicines Agency plans to appeal interim rulings on release of clinical trial data
  • Shook Hardy & Bacon LLP
  • European Union
  • May 16 2013

According to a news source, European Medicines Agency (EMA) Director Guido Rasi intends to appeal interim rulings recently issued by the European


EU medical device manufacturers address plan to change regulatory directives
  • Shook Hardy & Bacon LLP
  • European Union
  • February 8 2013

Eucomed, an organization that represents the interests of the European medical device industry, has issued a position paper that assesses a number of


Researchers protest ECJ advocate general’s position on patenting stem cell technologies
  • Shook Hardy & Bacon LLP
  • European Union
  • May 5 2011

Viewing the issue as a matter of morality, the advocate general of the European Court of Justice (ECJ) recently delivered a non-binding ruling that would render unpatentable the cells removed from the human embryo at the blastocyst stage, because the removal involves the embryo's destruction


Joint public meeting to focus on bridging nanotechnology research
  • Shook Hardy & Bacon LLP
  • European Union, USA
  • February 24 2011

The National Nanotechnology Coordination Office has announced that it will spearhead a public meeting to focus on "environmental health and safety questions for nanomaterials and nanotechnology-enabled products" and to "encourage joint US-EU programs of work that would leverage resources."


Report suggests Europe could become marine biotech leader by 2020
  • Shook Hardy & Bacon LLP
  • European Union
  • January 13 2011

The Marine Board of the European Science Foundation has released a report that suggests Europe could become a global leader in marine biotechnology by 2020, particularly by cultivating microalgae for fuel


Europe sees strong growth in biotech patent filings
  • Shook Hardy & Bacon LLP
  • European Union
  • April 21 2011

According to a news source, biotechnology patent applications filed with the European Patent Organization (EPO) grew more than 42 percent in 2010 from the previous year


News bytes
  • Shook Hardy & Bacon LLP
  • European Union, USA
  • December 16 2010

The European Medicines Agency (EMA) adopts two draft guidelines as part of the regulatory approval process for certain biosimilar medicinal products


EC approves first gene therapy medicine in western world
  • Shook Hardy & Bacon LLP
  • European Union
  • November 15 2012

The European Commission has given final approval to uniQure’s gene therapy Glybera for the treatment of lipoprotein lipase deficiency patients with recurring acute pancreatitis


EU regulators charge pharma companies with antitrust violations in pay-for-delay deals
  • Shook Hardy & Bacon LLP
  • European Union
  • August 2 2012

The European Commission (EC) has reportedly charged nine pharmaceutical companies with breaches of European Union (EU) antitrust rules for entering pay-for-delay deals with generic competitors